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Conclusions: The commonly used gamma index criteria of 
DD3%/DTA 3 mm distance to agreement may potentially mask 
clinically-relevant errors. Dose differences calculated from 
the maximum of prescribed doses to high fraction doses were 
less evident than for the local dose-differences method. For 
geometric errors the most precise results were obtained for 
high resolution SRS1000 array. All of the researched arrays 
proved good response for dose induced errors. Therefore, 
each detector and technique should be set to the proper 
gamma tolerance parameters to identify possible deviations 
from the treatment plan. 
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Purpose/Objective: To assess, by means of treatment plan 
comparison along with normal tissue complication probability 
(NTCP) modelling, the feasibility of subpopulation grouping 
according to tumour location in head and neck cancer (HNC) 
patients regarding identification of patients with highest 
benefit from intensity-modulated proton therapy (IMPT) 
compared to intensity-modulated photon therapy (IMRT). 
Furthermore, to assess the feasibility for both IMRT and IMPT 
of two different dose escalation (DE) levels with respect to 
NTCP. 
Materials and Methods: For 45 HNC patients IMRT was 
compared to IMPT with two different DE levels implemented 
via the simultaneous integrated boost technique. A treatment 
schedule was defined allowing for a patient stratification by 
functional imaging after 20 Gy of treatment according to risk 
of recurrence. Changes in patient anatomy during the course 
of treatment were considered using a one-time adaptation 
strategy. Evaluation of physical dose distributions and of the 
resulting NTCP values were performed using modern models 
for acute mucositis, xerostomia, aspiration, dysphagia, 
laryngeal oedema and trismus. Three patient subgroups were 
defined based on the primary tumour location: (A) in the 
upper head and neck area, (B) in the lower head and neck 
area, and (C) extending in both areas. 
Results: In general, IMPT reduced the NTCP values in 
comparison to IMRT while keeping similar target coverage for 
all patients. The level of reduction varied between different 
NTCP models (e.g. small: <1% for impact of swallowing liquid 
food, modest: 5% for mucositis, and large: >10% for physician 
rated dysphagia). Physical dose parameters were also 
reduced in most cases except for skin doses. Subgroup 
analyses showed a higher reduction of swallowing related 
side effects by IMPT for patients with tumours in the upper 
head and neck area (group A), while the risk of acute 
mucositis was reduced in patients with tumours in the larynx 
region (group B). For other toxicities based on NTCP 
evaluation, no subgroup-specific benefit by IMPT could be 
identified. Regardless of subgroups, the DE level had only 
little impact on most toxicity risks except for the aspiration 
model based on the pharyngeal constrictor muscles (PCM). 
Figure 1 illustrates changes in NTCP for the two treatment 
techniques (NTCPIMRT-NTCPIMPT: a-c) and for the two DE levels 
(NTCP2.6Gy-NTCP2.3Gy: d). 
Conclusions: IMPT reduced all NTCP values compared to 
IMRT. Subgrouping can help to identify patients who may 
benefit most from the use of IMPT. Thus, it can be a useful 
tool in the clinic where there are limited treatment 
resources. The individual benefit within the subgroups may 
differ and should be evaluated by individual treatment plan 
comparisons for selected patients. The used DE levels are 
both feasible as they did not impact the calculated NTCP 
values except for one. These results need to be confirmed in 
prospective clinical trials. 
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Purpose/Objective: The current plan optimization practice 
in radiotherapy involves a time consuming trial-and-error 
loop until the treatment planner finds one single optimal or 
near-optimal plan which is then evaluated by the radiation 
oncologist and the medical physicist (decision makers). In 
contrast, multi-criteria optimization (MCO) aims to avoid the 
iterative optimization loop and to provide alternative choices 
to the decision makers. MCO generates a set of Pareto-
optimal plans which are plans where no criterion can be 
improved without deteriorating another. This set of 
generated decision plans, available for real time navigation 
and decision making, are Pareto optimal in the fluence 
space. The final deliverable plan is created based on the 
navigated plan selected by decision makers, and entails a 
post-optimization step which includes segmentation and a 
final dose calculation. This two-step process could result in 
dosimetric differences between the selected plan and the 
final deliverable one. The purpose of this study was to 
explore the dose difference between navigated and actually 
deliverable plans through the trade-off between two 
evaluation parameters, planning target volume (PTV) under-
dosage and rectum sparing.  
Materials and Methods: Navigated and deliverable VMAT 
plans for five prostate cancer cases were created and 
calculated with RayStation Treatment Planning System. Two-
dimensional Pareto fronts were created corresponding to PTV 
under-dosage vs. rectum sparing. PTV under-dosage was 
evaluated through the volume of PTV receiving less than 95% 
of the prescribed dose and rectum sparing was evaluated 
through the D50% parameter for rectum. In order to minimize 
the effect of the other parameters involved in the treatment 
planning problem and to reduce the multi-dimensionality of 
the problem, we introduced optimization constraints on other 
OARs which ensured minimal dosimetric variations for these 
structures. 
Results: The Pareto front evaluation demonstrated a 
discrepancy for the trade-off parameters between navigated 
and final deliverable plans (see Figure 1). In two of the five 
prostate cases there was an improvement for the deliverable 
plans. For the other cases the discrepancy proved more 
random, resulting in better or worse final plans. Our results 
for prostate cases suggest that the final deliverable plan 
quality may be different from the one that has been used for 
decision making.  
 
Conclusions: The approximation error between the navigated 
and deliverable plans should be estimated and taken into 
consideration in the clinical decision making process when 
MCO is used. 
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Purpose/Objective: Treatment plan evaluation is a clinical 
decision problem with conflicting objectives. In clinical 
practice decision makers perform several clinical judgments 
based on trade-off analysis between tumor coverage and 
healthy tissue sparing in order to conclude if the plan is 
acceptable for treatment. Treatment plan evaluation process 
involves visual search and analysis in a contextually rich 
environment, including delineated structures and isodose 
lines superposed on CT data. Clinical decision making is a 
two-step process including visual analysis and clinical 
reasoning. To our knowledge, there have been no studies 
investigating where decision makers look when they evaluate 
a plan. Additionally, decision makers might not always be 
